ImageneBio (IMA) EBITDA Margin (2020 - 2025)

ImageneBio has disclosed EBITDA Margin across 6 years of filings, most recently posting 749.38% for Q1 2025.

• In Q1 2025, EBITDA Margin changed N/A year-over-year to 749.38%; the TTM figure through Sep 2025 stood at 1582.84% (down 79360.0% YoY), while the FY2023 annual figure was 823.33%, down 36934.0% from the prior year.
• EBITDA Margin came in at 749.38% for Q1 2025 at ImageneBio, down from 58.17% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 13.81% in Q4 2021 to a low of 5484.55% in Q2 2022.
• Average EBITDA Margin over 5 years is 1039.0%, with a median of 372.57% recorded in 2021.
• Year-over-year, EBITDA Margin jumped 4009535 bps in 2021 and sank 512707 bps in 2022.
• Over 5 years, EBITDA Margin stood at 13.81% in 2021, then tumbled by 2108 bps to 277.32% in 2022, then sank by 1099 bps to 3324.43% in 2023, then surged by 98 bps to 58.17% in 2024, then plunged by 1188 bps to 749.38% in 2025.
• Per Business Quant data, the three most recent EBITDA Margin figures were 749.38% in Q1 2025, 58.17% in Q3 2024, and 3324.43% in Q4 2023.